Clinical Trials Directory

Trials / Completed

CompletedNCT03474484

Calprotectin I Serum as a Diagnostic Marker

Calprotectin I in Serum as a Diagnostic Marker of Pneumonia in Patients Hospitalised With Acute COPD Exacerbation

Status
Completed
Phase
Study type
Observational
Enrollment
113 (actual)
Sponsor
St. Olavs Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Lower respiratory tract infection is the most common cause of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Patients diagnosed with pneumonia in addition to an AECOPD experience more severe clinical and laboratory disease manifestations, increase in-hospital morbidity and worse outcome. Clinicians have sought for new biomarkers that together with clinical assessments can improve the diagnostic accuracy of pneumonia in patients with AECOPD.The aim of the present study is to compare the accuracy of calprotectin with procalcitonin (PCT), C-reactive protein (CRP) and white blood cell count (WBC).

Conditions

Timeline

Start date
2018-04-03
Primary completion
2018-09-14
Completion
2018-09-14
First posted
2018-03-22
Last updated
2018-09-21

Locations

1 site across 1 country: Norway

Source: ClinicalTrials.gov record NCT03474484. Inclusion in this directory is not an endorsement.

Calprotectin I Serum as a Diagnostic Marker (NCT03474484) · Clinical Trials Directory